In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to ...

Team-NB heads consortium to develop open-source, single-entry-point digital assessment framework to replace “onerous” ...

Beiersdorf reveals its highly anticipated TopiC.A active ingredient for fighting acne is launching in a regimen under the ...

Financial disclosure documents for Heidi Overton, President Trump's nominee for FDA commissioner, are strikingly bare of the industry entanglements that have defined past commissioners, but are heavy ...

Nov. 12 deadline for limiting all THC to 0.3% concentration and 0.4mg per-container limit along with ban on synthetics ...

Memorandum of understanding between the two agencies allows them to share non-public information in order to improve ...

The FDA's breakthrough devices program reached 210 market authorizations as of June 30 — crossing the 200 mark— while Q3 ...

Roughly half of the FDA applications with September user fee goal dates involve pediatric populations, including four novel ...

The Bridge program may have enrolled 15% of eligible Part D beneficiaries after just two months, which raises questions about ...

Targeting patients with the TP53 Y220C mutation, thought to be present in about 3.2% of ovarian cancer cases, PMV says ...

The company still plans to file an NDA for envudeucitinib for psoriasis and said a prespecified analysis in the Phase IIb ...

Amgen’s Tavneos, which is licensed by CSL Vifor in Europe, can no longer be supplied to new patients in the UK, after the ...